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In the early events of human immunodeficiency virus type 1 (HIV-1) infection, immature dendritic cells
(DCs) expressing the DC-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) receptor
capture small amounts of HIV-1 on mucosal surfaces and spread viral infection to CD4 T cells in lymph nodes
(22, 34, 45). RNA interference has emerged as a powerful tool to gain insight into gene function. For this
purpose, lentiviral vectors that express short hairpin RNA (shRNA) for the delivery of small interfering RNA
(siRNA) into mammalian cells represent a powerful tool to achieve stable gene silencing. In order to interfere with
DC-SIGN function, we developed shRNA-expressing lentiviral vectors capable of conditionally suppressing DC-
SIGN expression. Selectivity of inhibition of human DC-SIGN and L-SIGN and chimpanzee and rhesus macaque
DC-SIGN was obtained by using distinct siRNAs. Suppression of DC-SIGN expression inhibited the attachment of
the gp120 envelope glycoprotein of HIV-1 to DC-SIGN transfectants, as well as transfer of HIV-1 to target cells in
trans. Furthermore, shRNA-expressing lentiviral vectors were capable of efficiently suppressing DC-SIGN expres-
sion in primary human DCs. DC-SIGN-negative DCs were unable to enhance transfer of HIV-1 infectivity to T cells
in trans, demonstrating an essential role for the DC-SIGN receptor in transferring infectious viral particles from
DCs to T cells. The present system should have broad applications for studying the function of DC-SIGN in the
pathogenesis of HIV as well as other pathogens also recognized by this receptor.
In addition to classical human immunodeficiency virus type
1 (HIV-1) receptors and coreceptors (CD4, CCR5, and
CXCR4), dendritic cells (DCs), such as those derived from
blood monocytes as well as those located beneath genital sur-
faces and within lymphoid tissues, express the DC-specific in-
tercellular adhesion molecule 3 (ICAM-3)-grabbing noninte-
grin (DC-SIGN, also known as CD209) receptor (28, 29). DC-
SIGN is a type II transmembrane protein with an external
C-type lectin domain that specifically recognizes glycan ligands
(18). Importantly, DC-SIGN binds the gp120 envelope glyco-
protein of HIV-1 (13, 22, 38) and facilitates the transmission of
HIV-1 from DC-SIGN transfectants to permissive CD4 T
cells (22, 24, 32, 38, 49). The natural ligands for DC-SIGN are
ICAM-3 and ICAM-2, molecules that contribute to transient
DC-T-cell attachment (23) and to transmigration of DCs
across vascular endothelia (21), respectively.
RNA interference (RNAi) is a sequence-specific posttran-
scriptional gene silencing mechanism initiated by the introduc-
tion of double-stranded RNA (dsRNA) into target cells (42).
RNAi is a natural regulatory mechanism conserved among
many organisms, including plants, Caenorhabditis elegans, Dro-
sophila, and mammals (42). RNAi is mediated by small inter-
fering RNAs (siRNAs) produced from long dsRNAs of exog-
enous or endogenous origin by an endonuclease called Dicer.
The resulting siRNAs are about 21 to 23 nucleotides long and
are incorporated into a nuclease complex, the RNA-induced
silencing complex, which then targets and cleaves mRNA that
is complementary to the siRNAs. Delivery of siRNAs into
mammalian cells by transfection with synthetic siRNAs or
DNA plasmids expressing short hairpin RNAs (shRNAs) has
been shown to mediate RNAi successfully (9, 16, 36, 46). Im-
portantly, recent reports describe the use of viral vectors to
deliver siRNAs successfully into mammalian cells in order to
get stable gene silencing (1, 3, 8, 15, 40, 48, 54, 56).
In order to provide a basis for studying in further detail the
role of DC-SIGN in HIV pathogenesis, we developed lentiviral
vectors conditionally expressing shRNAs targeting DC-SIGN.
The objective of the present study was to generate stable cell
lines as well as primary DCs deficient in DC-SIGN. Using this
approach, we examined the effect of DC-SIGN knockdown on
the attachment of the gp120 envelope glycoprotein of HIV-1 as
well as the transmission of virus to T cells in trans.
MATERIALS AND METHODS
Vector construction and siRNAs. The pSUPER, pSUPER-si-GFP (si-GFP),
pLV-Th, and pLV-tTR-KRAB-dsRed (LV-KRAB) constructs were described
previously (9, 54). Oligonucleotides encoding shRNAs directed against human
DC-SIGN mRNA were designed according to the method of Elbashir et al. (17)
and purchased from MWG Biotech (Ebersberg, Germany) (see Table 1 for
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siRNA sequences). These oligonucleotides were annealed and ligated into
pSUPER downstream of the H1 promoter, giving rise to pSUPER-siDC-SIGN
constructs (referred to hereafter as si-SIGN constructs). Both strands of si-SIGN
constructs were sequenced using T3 and T7 primers. The H1 promoter cassette
in pLV-TH was replaced by the H1-siRNA cassette excised from si-SIGN con-
structs, giving rise to LV-si-SIGN lentiviral vectors. Human DC-SIGN (23) and
L-SIGN (6) genes were cloned into lentiviral vectors pLOX (LV-DC-SIGN) and
pWPXL (LV-L-SIGN), respectively, replacing the green fluorescent protein
(GFP) marker gene. Chimpanzee and rhesus macaque DC-SIGN expression
plasmids were described previously (20).
siRNA screening test. Subconfluent 293T cells were cotransfected with 5 g of
pSUPER control plasmid or si-SIGN constructs and 0.5 g of human DC-SIGN
and pEGFP-N1 (Clontech, Palo Alto, Calif.) expression plasmids by calcium
phosphate precipitation. Medium was changed after 16 h, and 24 h later, flow
cytometric analysis of GFP and DC-SIGN expression using phycoerythrin (PE)-
labeled anti-human DC-SIGN monoclonal antibody (MAb) was performed. To
test for the specificity of si-SIGN constructs, the same assay was performed with
the human DC-SIGN expression plasmid replaced by a plasmid expressing L-
SIGN (PE-labeled anti-human L-SIGN MAb) or chimpanzee or rhesus macaque
DC-SIGN (PE-labeled anti-human DC-SIGN MAb).
Production of lentiviral vectors. All recombinant lentiviruses were produced
by transient transfection of 293T cells according to standard protocols (58).
Briefly, subconfluent 293T cells were cotransfected with 20 g of the plasmid
vector, 15 g of pCMV-deltaR8.91, and 5 g of pMD2G-VSVG by calcium
phosphate precipitation. Vector titers were determined by transduction and flow
cytometric analysis of GFP expression in HeLa cells. Titers ranged between 2 
107 and 5  108 HeLa-transducing U per ml.
Viral stocks. Viral stocks were generated by transfection of 293T cells with
calcium phosphate-coprecipitated proviral plasmid pR9 which carries a full-
length HIV-1 X4 strain (19). Infectious titers of viral stocks were evaluated by
limiting dilution on HeLa P4 cells (11) and expressed as infectious units per
milliliter. The titer values were also determined by measuring HIV-1 p24gag by
using an enzyme-linked immunosorbent assay (ELISA) kit (Beckman Coulter,
Paris, France).
Generation of cell lines stably expressing siRNAs. Raji B cells were cultured
as described elsewhere (55). Various Raji cell lines stably expressing siRNAs
were generated by transduction with LV-DC-SIGN, LV-si-SIGN8, LV-si-
SIGN11, LV-si-SIGN26, LV-L-SIGN, or empty vector. The HeLa P4-R5 cell
lines stably expressing siRNAs were generated by transduction with LV-DC-
SIGN, LV-si-SIGN8, LV-si-SIGN11, or LV-si-SIGN26. Stable knockdown or
expression of the genes of interest by the different cell lines was determined by
flow cytometric analysis.
Preparation and transduction of DC progenitors. Cord blood samples were
obtained according to institutional guidelines of the ethical committee. CD34
cells were purified and cultured as previously described (4). DC progenitors were
transduced and analyzed on a FACSCalibur cell analyzer (Becton Dickinson,
Mountain View, Calif.) as reported in reference 41 with the following modifica-
tions. After 3 to 6 weeks of primary culture, DC progenitors were transduced
with LV-si-SIGN lentiviral vectors at a multiplicity of infection (MOI) of 20 for
16 h in the presence of hematopoietic growth factors. Cells were then extensively
washed, and 2  105 transduced DC progenitors per ml of Iscove’s modified
Dulbecco medium Glutamax I supplemented with 10% fetal calf serum and
antibiotics (Gibco BRL, Paisley, United Kingdom) were induced to differentiate
into immature DCs for 6 days with a solution containing 50 ng/ml each granu-
locyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4;
Strathmann Biotec, Hamburg, Germany) in the presence of 50 M 2-mercap-
toethanol (Sigma, Buchs, Switzerland) or into mature DCs by further addition of
20 ng of lipopolysaccharide (LPS; Escherichia coli strain 055:B5; Difco, Detroit,
Mich.)/ml for the last 2 days. DCs were harvested at day 6, analyzed by flow
cytometry, and used in subsequent assays.
Cellular sorting. Immature DCs were sorted on a FACSVantage SE cell sorter
(Becton Dickinson) as GFP positive-DC-SIGN negative (LV-si-SIGN11) or
GFP positive-DC-SIGN negative (empty vector). Cells were systematically re-
analyzed after sorting. Viability and correctness of surface phenotype were ex-
cellent (95%) up to 24 h postsorting. Sorted cells were counted and used for
viral assays as described below.
Analysis of DC-SIGN-mediated transfer of HIV-1 infection to target cells. In
order to measure DC-SIGN-mediated trans-enhancement of HIV-1 infection of
T cells, aliquots of 5  103 Raji transfectants or sorted DCs were incubated for
2 h with HIV-R9 virus at 37°C at a MOI of 0.001, extensively washed, and directly
cocultured with activated peripheral blood leukocytes (PBLs). Viral production
in the coculture supernatants was monitored by reverse transcriptase assay.
Flow cytometric analysis and MAbs. Flow cytometric analysis was performed
as described previously (5). Cells were analyzed on a FACSCalibur cell analyzer
(Becton Dickinson). Data were analyzed using WINMDI software by J. Trotter
at Scripps Institute (La Jolla, Calif.).
PE-labeled MAbs were obtained as follows: anti-CD209 (DC-SIGN; mouse
immunoglobulin G2b [mIgG2b], clone 120507) and anti-CD209L (L-SIGN;
mIgG2b, clone 120604) from R&D Systems (Minneapolis, Minn.); anti-CD4
(mIgG1, clone MT310) from Dako (Glostrup, Denmark); and anti-CD34
(mIgG1, clone 8G12), anti-CD1a (mIgG1, clone HI146), anti-CD83 (mIgG1,
clone HB15e), anti-CD206 (macrophage mannose receptor; mIgG1, clone 19.2),
and anti-HLA-ABC (mIgG1, clone G46-2.7) from PharMingen (San Diego,
Calif.). Allophycocyanin (APC)-labeled MAbs were obtained as follows: anti-
CXCR4 (mIgG2a, clone 12G5) from PharMingen and anti-CD209 (DC-SIGN;
rat IgG2a, clone eB-h209) from eBiosciences (San Diego, Calif.). Monoclonal
isotype controls were obtained as follows: PE-labeled mIgG1 and mIgG2b and
APC-labeled mIgG2a from PharMingen and APC-labeled rat IgG2a from eBio-
sciences.
Fluorescent-bead adhesion assay. The fluorescent-bead adhesion assay was
performed as previously described (25). Carboxylate-modified TransFluor-
Spheres (488/645 nm; 1.0 m; Molecular Probes, Eugene, Oreg.) were coated
with ICAM-3, monomeric HIV gp120, or Mycobacterium tuberculosis-derived
mannose-capped lipoarabinomannan (ManLAM) as described previously (25,
26). Fifty thousand cells were preincubated or not with anti-human DC-SIGN
neutralizing MAb AZN-D2 (20 g/ml) or mannan (1 mg/ml; Sigma) for 45 min
at 37°C. Ligand-coated fluorescent beads (20 beads/cell) were added, and the
suspension was incubated for 30 min at 37°C. Adhesion was determined by flow
cytometric analysis using the FACSVantage SE (Becton Dickinson) by measur-
ing the percentage of cells within the GFP-positive cell population that had
bound fluorescent beads.
RT-PCR. Total RNA was extracted from Raji cell lines by using TRIzol
reagent (Life Technologies, Basel, Switzerland). One hundred nanograms of
FIG. 1. Design and screening of siRNAs targeting human DC-
SIGN expression. (A) Design of siRNAs. Six different siRNAs against
DC-SIGN were designed to target distinct parts of the DC-SIGN
mRNA sequence. siRNA11 targeted tandem repeats (R1 to R8)
present in exon III. TM, transmembrane domain. (B) Screening of
siRNA-expressing vectors. Subconfluent 293T cells were cotransfected
with pSUPER control plasmid, si-GFP, or si-SIGN constructs along
with human DC-SIGN and pEGFP-N1 expression plasmids. The mean
fluorescence intensity of DC-SIGN and GFP expression was measured
in the GFP-positive and the DC-SIGN-positive cell populations, re-
spectively. Histograms show the percentages of inhibition relative to
that under the pSUPER control experimental condition. Means 
standard errors of results from four independent experiments are
shown.
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total RNA was subjected to SuperScript one-step reverse transcription (RT)-
PCR with Platinum Taq (Invitrogen, Basel, Switzerland) to assess levels of
mRNA corresponding to DC-SIGN and the cyclophilin gene as a housekeeping
gene. Oligonucleotides with the following sequences (5 to 3) were purchased
from MWG Biotech: DC-SIGN forward, GAGTGACTCCAAGGAACCAAGA
CTGCA, and DC-SIGN reverse, GGTAGATCGCGTCTTGCCTGGATTGTT,
amplifying a 233-bp PCR product, and cyclophilin forward, GGTCAACCCCA
CCGTGTTCTTCGACAT, and cyclophilin reverse, GACTTGCCACCAGTGC
CATTATGGCGT, amplifying a 228-bp PCR product.
IFN-/ response. The amounts of alpha interferon (IFN-) in the superna-
tants of Raji cell lines or day-6 transduced immature DCs were measured with an
IFN- ELISA kit (5 to 500 pg/ml; PBL Biomedical Laboratories, New Bruns-
wick, N.J.) according to the manufacturer’s instructions. Levels of mRNA cor-
responding to the classic IFN target gene, the 2,5-oligoadenylate synthetase
gene, were measured using SuperScript one-step RT-PCR as previously de-
scribed (7).
RESULTS
siRNA-expressing vectors suppress DC-SIGN expression. In
order to silence human DC-SIGN expression, we followed the
design rules of Elbashir et al. (17) and found 41 different
siRNAs potentially targeting the DC-SIGN gene. Among
them, six siRNAs corresponding to distinct parts of the DC-
SIGN cDNA sequence were chosen (Fig. 1A; siRNA se-
quences are indicated in Table 1). siRNAs were cloned into
pSUPER downstream of the H1 promoter, giving rise to si-
SIGN constructs.
The ability of each siRNA to inhibit DC-SIGN expression
was then tested by cotransfection of 293T cells with pSUPER
control plasmid, pSUPER-si-GFP, or si-SIGN constructs along
with human DC-SIGN and pEGFP-N1 expression plasmids.
This knockdown screening test allowed the identification of
four siRNAs effective at inhibiting DC-SIGN expression as
assessed by flow cytometric analysis (Fig. 1B). si-SIGN11 was
the most effective (97% inhibition) while not affecting GFP
expression. si-SIGN11 titration showed dose-dependent inhi-
bition of DC-SIGN expression (data not shown). The same
assay was used to test the siRNAs against human L-SIGN,
rhesus macaque DC-SIGN, and chimpanzee DC-SIGN. Inter-
estingly, some siRNAs could inhibit human L-SIGN as well as
primate DC-SIGN expression despite the presence of mis-
matches between siRNA and specific mRNA sequences (Table
2). Again, si-SIGN11 was the most effective at inhibiting hu-
man L-SIGN and primate DC-SIGN. Interestingly, only si-
SIGN8 specifically inhibited human DC-SIGN.
Lentivirus-mediated delivery of siRNA suppresses DC-
SIGN expression in cell lines. siRNAs were then cloned into
lentiviral vectors for stable expression in cell lines (54). In
order to evaluate the effectiveness of siRNA-expressing
lentiviral vectors (referred to hereafter as LV-si-SIGN) at in-
hibiting DC-SIGN expression, various Raji cell lines stably
expressing siRNAs were generated (Fig. 2A). Transduction
with LV-si-SIGN8 or LV-si-SIGN11 along with LV-DC-SIGN
induced suppression of DC-SIGN expression. Results of flow
cytometric analysis of DC-SIGN expression on Raji stable
transfectants correlated with the results obtained using the
knockdown screening test described above (Fig. 1B and 2A).
LV-si-SIGN8 did not inhibit L-SIGN expression, confirming
the specificity of the vector for DC-SIGN downregulation (Fig.
2A and Table 2). It is of note that stable DC-SIGN knockdown
could be observed over 6 months (data not shown).
To ensure that DC-SIGN downregulation occurred through
RNAi and not translational repression through a micro-RNA
mechanism, levels of mRNA encoding DC-SIGN in different
Raji cell lines stably expressing siRNAs were measured by
RT-PCR (Fig. 2B). Very low levels of DC-SIGN mRNA were
found in Raji cell lines transduced with LV-si-SIGN8 or LV-
si-SIGN11 compared to those in control cell lines, whereas
levels comparable to those in the DC-SIGN-expressing cell
line were found in cell lines transduced with LV-si-SIGN26.
In addition, we studied the effect of DC-SIGN-specific
siRNAs on the expression of the CD4 receptor and the
CXCR4 coreceptor involved in HIV binding. For this purpose,
various HeLa P4-R5 cell lines stably expressing siRNAs were
TABLE 1. Human DC-SIGN cDNA target sequences for siRNAsa
siRNA Exon Sequence (5 to 3)
siRNA2 I AACAGCTGAGAGGCCTTGGAT
siRNA3 II AACTCCTCTCCTTCACGCTCT
siRNA8 III AAGACGCGATCTACCAGAACC
siRNA11 III AAGGCTGCAGTGGGTGAGCTT
siRNA26 IV AACTGGCACGACTCCATCACC
siRNA35 VI AAGACTGCGCGGAATTTAGTG
a Six different siRNAs directed against human DC-SIGN were designed to
correspond to distinct parts of the DC-SIGN mRNA sequence. Target sequences
of the DC-SIGN cDNA and corresponding exons are shown.
TABLE 2. siRNA specificitya
Construct
Inhibition of:
Human DC-SIGN Human L-SIGN Chimpanzee DC-SIGN Rhesus macaque DC-SIGN
si-SIGN2  (0)  (Ø)  (0)  (Ø)
si-SIGN3  (0)  (1)  (0)  (0)
si-SIGN8  (0)  (1)  (1)  (2)
si-SIGN11b  (0/0/0/0/0/0)  (2/2/2/2/2/2)  (0/0/0/0/0/0)  (1/0/0/2/2/5)
si-SIGN26  (0)  (1)  (1)  (0)
si-SIGN35  (0)  (1)  (0)  (1)
a Subconfluent 293T cells were cotransfected with pSUPER control plasmid, si-GFP, or si-SIGN constructs along with human DC-SIGN and pEGFP-N1 expression
plasmids. Flow cytometric analysis of DC-SIGN expression was performed. The mean fluorescence intensity of DC-SIGN expression was measured in the GFP-positive
cell population. To test for the specificity of si-SIGN constructs, the same assay was performed with the human DC-SIGN expression plasmid replaced by plasmids
expressing L-SIGN or chimpanzee or rhesus macaque DC-SIGN. Percentages of inhibition relative to that under the pSUPER control experimental condition were
then calculated. , strong inhibition; , inhibition; , no inhibition. The numbers within brackets correspond to mismatches between siRNAs and specific mRNA
sequences. Ø, no significative homology.
b si-SIGN11 targets six repeated sequences with 100% homology on the human DC-SIGN mRNA.
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generated. Whereas transduction with LV-si-SIGN11 induced
significant suppression of DC-SIGN expression, CD4 and
CXCR4 expression levels were not affected (data not shown).
Identical results were obtained using LV-si-SIGN8 (data not
shown).
Suppression of DC-SIGN expression by drug-inducible
siRNAs. Various HeLa cell lines were generated by transduc-
tion with LV-DC-SIGN, LV-si-SIGN11, and LV-KRAB to
allow for conditional suppression of DC-SIGN (Fig. 3). Cells
cotransduced with these three lentiviral vectors normally ex-
pressed DC-SIGN when cultured in the absence of doxycy-
cline, owing to LV-KRAB-mediated suppression of siRNA
synthesis (54). In contrast, addition of the drug relieved this
inhibition and allowed for DC-SIGN downregulation. Expres-
sion of GFP was also subjected to conditional LV-KRAB re-
pression, providing an internal monitoring device. Conditional
suppression of DC-SIGN expression could also be obtained
using LV-si-SIGN8 (data not shown).
siRNA-expressing lentiviral vectors do not activate IFN
pathways. One concern with siRNA technology is the capacity
of dsRNA to trigger IFN-dependent pathways in some cellular
systems (7, 14, 43). In order to test whether LV-si-SIGN acti-
vated IFN pathways, we measured IFN- in culture superna-
tants of Raji cell lines transduced with LV-si-SIGN. Using a
highly sensitive ELISA, we could not detect measurable levels
of IFN- (data not shown). Furthermore, we did not observe
any significant differences in the levels of mRNA correspond-
ing to IFN target gene the 2,5-oligoadenylate synthetase gene
by using a semiquantitative RT-PCR (data not shown). While
we cannot entirely rule out that highly sensitive tests such as
DNA microarrays could detect modifications in cells after
transduction with LV-si-SIGN, these results indicate that no
significant activation of IFN-dependent pathways occurred in
our system.
Transduction of DC progenitors with siRNA-expressing len-
tiviral vectors allows the generation of DC-SIGN-negative
DCs. We next evaluated the potential of siRNA-expressing
lentiviral vectors to suppress DC-SIGN expression at the sur-
face of DCs. For this purpose, we transduced DC progenitors
amplified in vitro from cord blood CD34 cells with Flt3 li-
gand, stem cell factor, and thrombopoietin (4, 41). Transduced
DC progenitors were then induced to differentiate into imma-
ture DCs for 6 days with GM-CSF and IL-4. Flow cytometric
analysis of DCs revealed that LV-si-SIGN11 completely sup-
pressed DC-SIGN expression compared to that in control cells
or cells transduced with the inefficient LV-si-SIGN26 (Fig.
4A). LV-si-SIGN8 was less potent in inhibiting DC-SIGN ex-
pression, although the majority of the cells showed receptor
knockdown. CD1a expression levels were comparable between
GFP-positive and GFP-negative DCs (data not shown). A sim-
FIG. 2. Suppression of DC-SIGN expression in cell lines through
lentivirus-mediated delivery of siRNAs. (A) Generation of cell lines
stably expressing siRNAs. Stable Raji transfectants were generated by
transduction with the indicated lentiviral vectors. While both LV-si-
SIGN8 and LV-si-SIGN11 suppressed DC-SIGN expression, only LV-
si-SIGN11 suppressed L-SIGN expression. One month posttransduc-
tion, flow cytometric analysis of GFP, DC-SIGN, and L-SIGN
expression was performed. The percentages of cells positive for the
indicated cell surface markers are shown. (B) Effect of siRNAs on
DC-SIGN mRNA. Total RNA extracted from Raji transfectants was
subjected to RT-PCR to assess levels of mRNA corresponding to
DC-SIGN and cyclophilin. Both LV-si-SIGN8 and LV-si-SIGN11
downregulated DC-SIGN mRNA expression but not cyclophilin
mRNA expression.
FIG. 3. Conditional suppression of DC-SIGN expression was eval-
uated in HeLa cell lines transduced with LV-DC-SIGN, LV-si-
SIGN11, and LV-KRAB in the presence () or absence () of doxy-
cycline (DOX). One week posttransduction, flow cytometric analysis of
GFP and DC-SIGN expression was performed. Cell percentages cor-
responding to each quadrant of two-dimensional plots are shown.
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ilar phenotype for DC-SIGN was obtained using LPS as a
maturation factor. Upregulation of HLA-DR and CD83 as
well as downregulation of macrophage mannose receptor
(CD206) was always observed upon maturation with LPS (Fig.
4B). In addition, transduction with lentiviral vectors did not
modulate the expression of HLA-ABC, CD4, or CXCR4 (data
not shown). Finally, no IFN- could be detected in the super-
natants of day-6 transduced immature DCs (data not shown).
In conclusion, siRNA-expressing lentiviral vectors targeting
DC-SIGN allowed for efficient and specific knockdown of this
receptor on immature and mature DCs.
DC-SIGN knockdown impedes HIV-1 gp120 adhesion to
target cells. To test the ability of LV-si-SIGN to inhibit HIV-1
gp120 attachment to Raji transfectants (Fig. 5A) or DC-SIGN-
negative DCs (Fig. 5B), we used a well-established fluorescent-
bead adhesion assay (23, 25). Beads coated with HIV-1 gp120,
M. tuberculosis cell wall component ManLAM, or ICAM-3
were incubated with cells stably expressing siRNAs. HIV-1
gp120, ManLAM, and ICAM-3 binding to cells transduced
with LV-si-SIGN11 was severely reduced (Fig. 5). The levels of
inhibition obtained using this assay were consistently reproduc-
ible with LV-si-SIGN11, but mannan or blocking antibodies
showed more intra-assay variation (data not shown).
DC-SIGN knockdown severely reduces trans-enhancement
of HIV-1 infection of T cells. Finally, we investigated whether
DC-SIGN-negative DCs were capable of trans-enhancing
HIV-1 infectivity in activated PBLs. Similar results were ob-
tained using primary human DCs and Raji DC-SIGN transfec-
tants (Fig. 6). While sorted DCs transduced with a control
lentiviral vector could enhance the transfer of small amounts of
virus HIV-R9 (MOI of 0.001) to activated PBLs, the same
amount of virus in medium alone or added to DC-SIGN-
negative DCs could not be transferred to activated PBLs (Fig.
FIG. 4. Generation of DCs with DC-SIGN expression knocked
down. DC progenitors were transduced with the indicated lentiviral
vectors and differentiated either into immature DCs for 6 days with
GM-CSF and IL-4 or into mature DCs by addition of LPS for the last
2 days of culture. Immature or mature DCs harvested at day 6 were
analyzed by flow cytometry for the indicated cell surface antigens.
LV-si-SIGN8 and LV-si-SIGN11 specifically inhibited DC-SIGN ex-
pression in DCs, and control vectors did not. Cell percentages corre-
sponding to each quadrant of two-dimensional plots are shown. Rep-
resentative results from one experiment out of four are presented.
FIG. 5. Effect of DC-SIGN knockdown on HIV-1 gp120 adhesion.
Raji transfectants (A) or transduced immature DCs (B) were resus-
pended in adhesion buffer and preincubated with anti-DC-SIGN neu-
tralizing MAb (AZN-D2), mannan, or medium alone for 45 min at
37°C. Carboxylate-modified TransFluorSpheres coated with ICAM-3,
gp120, or ManLAM were added, and the suspension was incubated for
30 min at 37°C. Adhesion was determined by measuring the percent-
ages of cells with bound fluorescent beads within the GFP-positive cell
population by flow cytometric analysis. The results shown are repre-
sentative of those from three independent experiments giving similar
results.
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6B). These data confirm the role of DC-SIGN as a crucial HIV
receptor that mediates HIV-1 transmission from DCs to T
cells.
DISCUSSION
Here we describe a novel system that enables potent sup-
pression of DC-SIGN expression in a conditional manner. In
order to disturb DC-SIGN expression, we developed lentiviral
vectors conditionally expressing shRNAs targeting DC-SIGN.
These tools allowed for the efficient suppression of DC-SIGN
expression in various cell lines and in primary human DCs. By
silencing DC-SIGN expression, we could inhibit the attach-
ment of the gp120 envelope glycoprotein of HIV-1 to DCs
negative for DC-SIGN as well as the transfer of HIV infection
from DCs to T cells in trans.
Knockdown of DC-SIGN in DC precursors derived from
CD34 hematopoietic stem cells also revealed that this C-type
lectin is not required for DC ontogeny, and this finding is
compatible with the main role of DC-SIGN as a pathogen
recognition receptor. Indeed, DC-SIGN plays a major role in
the capture of HIV and M. tuberculosis on some DC subtypes
(34, 35). However, other DC subtypes, such as Langerhans
cells, do not express DC-SIGN and may mediate transfer of
HIV through additional molecules or may require productive
infection to transfer HIV to T cells (30, 37, 50, 51). In addition,
the versatility of lentiviral vectors should enable the knock-
down of DC-SIGN in a large number of targets, including
transgenic animals. Indeed, advances in RNAi technology have
provided a rapid loss-of-function method for assessing gene
function in mammalian cells (9, 16). Moreover, highly stable
and functional systems for silencing of gene expression in an-
imal models are available (31, 40, 44, 53). In particular, a
recent report describes a lentivirus-based system to function-
ally silence genes in transgenic mice by RNAi (40). Therefore,
the generation of transgenic animals which would help to elu-
cidate DC-SIGN function in HIV or simian immunodeficiency
virus (SIV) pathogenesis is currently possible.
Furthermore, DC-SIGN can bind nonviral pathogens such
as Leishmania mexicana (12), Schistosoma mansoni (52), M.
tuberculosis (26, 47), Helicobacter pylori (52), and Candida al-
bicans (10), as well as viral pathogens including Ebola virus (2),
SIV-1, SIV-2 (38), HIV-2 (38), cytomegalovirus (27), hepatitis
C virus (33, 39), and severe acute respiratory syndrome coro-
navirus (57). Therefore, our system based on lentivirus-medi-
ated delivery of drug-inducible siRNAs targeting DC-SIGN
will allow for new insights on this pathogen recognition recep-
tor.
Another important application of our system is to reassess
DC-SIGN functions. Most results described so far on the role
of DC-SIGN relied on the use of blocking antibodies and
mannan (22, 49). While these blocking agents are valuable,
significant variations may be observed between results of stud-
ies using these tools because the block depends on the affinity
of DC-SIGN for its ligand compared to that for the inhibitor
used. The system developed here is nonequivocal because it is
not affected by the binding properties of inhibitors that are
more or less specific on diverse cell types. Lentiviral vectors
conditionally expressing shRNAs targeting DC-SIGN could
also be used in monocyte-derived DCs. However, we expect a
less-efficient downregulation of DC-SIGN, because monocytes
are more refractory to transduction than CD34 cell-derived
DC precursors (35; J.-F. Arrighi and V. Piguet, unpublished
results). Furthermore, DC-SIGN is expressed at very high lev-
els when monocytes are incubated in GM-CSF and IL-4 for 24
to 48 h (23), potentially limiting the effect of lentivirus-medi-
ated RNAi of this receptor in this system.
Using lentiviral vector-mediated RNAi, we could demon-
strate the unique role of DC-SIGN in enhancing transfer of
HIV infectivity from DCs to T lymphocytes in trans. Finally,
knockdown of DC-SIGN on primary DCs enables us to study
unequivocally the function of this receptor in early events of
HIV infection as well as its role in the pathogenesis of other
viruses recognized by DC-SIGN.
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